{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:26:39Z","timestamp":1777418799221,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bial Portela & Companhia S.A"},{"name":"Harlan Laboratories Ltd."},{"name":"Mar\u00eda Jes\u00fas Pablo, Envigo"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.yrtph.2019.104555","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T12:26:58Z","timestamp":1577104018000},"page":"104555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Oral repeated-dose toxicity studies of BIA 10\u20132474 in beagle dogs"],"prefix":"10.1016","volume":"111","author":[{"given":"Jerry F.","family":"Hardisty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6316-3179","authenticated-orcid":false,"given":"Wallace A.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2019.104555_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.chembiol.2009.02.013","article-title":"Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain","volume":"16","author":"Ahn","year":"2009","journal-title":"Chem. Biol."},{"key":"10.1016\/j.yrtph.2019.104555_bib2","first-page":"629","article-title":"In-vivo selectivity profiling of BIA 10-2474 against serine hydrolases in the rat brain","volume":"28","author":"Bonif\u00e1cio","year":"2018","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.yrtph.2019.104555_bib3","series-title":"Report by the Temporary Specialist Scientific Committee (TSSC): FAAH (Fatty Acid Amide Hydrolase),\u201d on the Causes of the Accident during a Phase 1 Clinical Trial in Rennes in January 2016","author":"CSST","year":"2016"},{"key":"10.1016\/j.yrtph.2019.104555_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008877-200402000-00001","article-title":"Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development","volume":"15","author":"De Vry","year":"2004","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104555_bib5","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","article-title":"A multiple comparison procedure for comparing several treatments with a control","volume":"50","author":"Dunnett","year":"1955","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.yrtph.2019.104555_bib6","article-title":"Preliminary safety evaluation in study BIA-10-2474-101","volume":"16","author":"Gama","year":"2016","journal-title":"Proc. Br. Paedodontic Soc."},{"key":"10.1016\/j.yrtph.2019.104555_bib7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/0192623308315670","article-title":"Spontaneous and age-related testicular findings in beagle dogs","volume":"36","author":"Goedken","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2019.104555_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/187152709789824660","article-title":"The endocannabinoid system and pain","volume":"8","author":"Guindon","year":"2009","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.yrtph.2019.104555_bib9","article-title":"Developmental and reproductive toxicity studies of BIA 10-2474","author":"Harris","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104555_bib10","article-title":"Oral repeated-dose toxicity studies of BIA 10-2474 in Wistar rat","author":"Hayes","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104555_bib11","article-title":"The absence of genotoxicity of a novel fatty acid amide hydrolase inhibitor, BIA 10-2474","author":"Hayes","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104555_bib12","article-title":"Oral repeated-dose toxicity studies of BIA 10-2474 in CD-1 mice","author":"Hayes","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104555_bib13","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJMoa1604221","article-title":"Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase","volume":"375","author":"Kerbrat","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yrtph.2019.104555_bib14","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/cmdc.201800393","article-title":"Discovery of a potent, long-acting, and CNS-active inhibitor (BIA 10-2474) of fatty acid amide hydrolase","volume":"13","author":"Kiss","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.yrtph.2019.104555_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5414\/CPP43217","article-title":"Adverse events in volunteers participating in phase I clinical trials: a single-center five-year survey in 1,559 subjects","volume":"43","author":"Lutfullin","year":"2005","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2019.104555_bib16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.yrtph.2016.05.002","article-title":"Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials","volume":"80","author":"Mead","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104555_bib17","series-title":"Simultaneous Statistical Inferences","author":"Miller","year":"1981"},{"key":"10.1016\/j.yrtph.2019.104555_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.yrtph.2019.104555_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/cpt.118","article-title":"Cannabinoid abuse and addiction: clinical and preclinical findings","volume":"97","author":"Panlilio","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2019.104555_bib20","first-page":"51","article-title":"FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels","volume":"11","author":"Petrosino","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.yrtph.2019.104555_bib21","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/019262330002800603","article-title":"Spontaneous testicular lesions in purpose-bred beagle dogs","volume":"28","author":"Rehm","year":"2000","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2019.104555_bib22","article-title":"Tolerability, pharmacokinetic and pharmacodynamic profile of BIA 10-2474 in healthy volunteers following multiple ascending doses","volume":"16","author":"Rocha","year":"2016","journal-title":"Proc. Br. Paedodontic Soc."},{"key":"10.1016\/j.yrtph.2019.104555_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s002280050413","article-title":"Adverse events in phase-I studies: a report in 1015 healthy volunteers","volume":"54","author":"Sibille","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104555_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/brain\/awt326","article-title":"PNPLA6 mutations cause Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum","volume":"137","author":"Synofzik","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.yrtph.2019.104555_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lfs.2018.04.054","article-title":"Enhanced endocannabinoid tone as a potential target of pharmacotherapy","volume":"204","author":"Toczek","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.yrtph.2019.104555_bib26","doi-asserted-by":"crossref","first-page":"E2067","DOI":"10.1210\/jc.2014-1836","article-title":"Loss-of-Function mutations in PNPLA6 encoding neuropathy target esterase underlie pubertal failure and neurological deficits in Gordon Holmes syndrome","volume":"99","author":"Topaloglu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.yrtph.2019.104555_bib27","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aaf7497","article-title":"Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474","volume":"356","author":"van Esbroeck","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.yrtph.2019.104555_bib28","article-title":"Oral repeated-dose toxicity studies of BIA 10-2474 in Cynomolgus monkeys","author":"Weber","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2019.104555_bib29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.5414\/CPP48563","article-title":"The safety of healthy volunteers in First-in-Man trials - an analysis of studies conducted at the Bayer in-house ward from 2000 to 2005","volume":"48","author":"Wensing","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230019303198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230019303198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:29:17Z","timestamp":1759494557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230019303198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":29,"alternative-id":["S0273230019303198"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.104555","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral repeated-dose toxicity studies of BIA 10\u20132474 in beagle dogs","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2019.104555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104555"}}